Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma

APMIS

Volumn 122, Issue 3, 2014, Pages 206-214

  Lee, Sung Wei ^a   Lin, Ching Yih ^a,b   Tian, Yu Feng ^a,c   Sun, Ding Ping ^a   Lin, Li Ching ^a   Chen, Li Tzong ^d,e,f   Hsing, Chung Hsi ^a   Huang, Chiang Ting ^g   Hsu, Han Ping ^h   Huang, Hsuan Ying ⁱ   Wu, Li Ching ^j   Li, Chien Feng ^a,b,d,j   Shiue, Yow Ling ^g  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^j CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

more..

Author keywords

CDC28 protein kinase regulatory subunit 1B; CKS1B; Nasopharyngeal carcinoma; Survival

Indexed keywords

CDC28 PROTEIN KINASE REGULATORY SUBUNIT 1B; CYCLIN DEPENDENT KINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DATA MINING; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; UPREGULATION;

CDC28 PROTEIN KINASE REGULATORY SUBUNIT 1B; CKS1B; NASOPHARYNGEAL CARCINOMA; SURVIVAL;

CDC2-CDC28 KINASES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84893815176     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12136     Document Type: Article

References (50)

1. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004;5:423-8.
2. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1765-77.
3. Jeyakumar A, Brickman TM, Doerr T Review of nasopharyngeal carcinoma. Ear Nose Throat J 2006;85:168-70, 72-3, 84.
4. Chou J, Lin YC, Kim J, You L, Xu Z, He B, et al. Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 2008;30:946-63.
5. Hadwiger JA, Wittenberg C, Mendenhall MD, Reed SI. The Saccharomyces cerevisiae CKS1 gene, a homolog of the Schizosaccharomyces pombe suc1 + gene, encodes a subunit of the Cdc28 protein kinase complex. Mol Cell Biol 1989;9:2034-41.
6. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004;428:190-3.
7. Hayles J, Aves S, Nurse P. suc1 is an essential gene involved in both the cell cycle and growth in fission yeast. EMBO J 1986;5:3373-9.
8. Tang Y, Reed SI. The Cdk-associated protein Cks1 functions both in G1 and G2 in Saccharomyces cerevisiae. Genes Dev 1993;7:822-32.
9. Patra D, Dunphy WG. Xe-p9, a Xenopus Suc1/Cks homolog, has multiple essential roles in cell cycle control. Genes Dev 1996;10:1503-15.
10. Polinko ES. S Strome. Depletion of a Cks homolog in C. elegans embryos uncovers a post-metaphase role in both meiosis and mitosis. Curr Biol 2000;10:1471-4.
11. Westbrook L, Manuvakhova M, Kern FG, Estes NR. 2nd, HN Ramanathan, JV Thottassery. Cks1 regulates cdk1 expression: a novel role during mitotic entry in breast cancer cells. Cancer Res 2007;67:11393-401.
12. Wolthuis R, Clay-Farrace L, van Zon W, Yekezare M, Koop L, Ogink J, et al. Cdc20 and Cks direct the spindle checkpoint-independent destruction of cyclin A. Mol Cell 2008;30:290-302.
13. Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology 2008;47:503-10.
14. Wang XC, Tian J, Tian LL, Wu HL, Meng AM, Ma TH, et al. Role of Cks1 amplification and overexpression in breast cancer. Biochem Biophys Res Commun 2009;379:1107-13.
15. Hui AB, Lo KW, Leung SF, Teo P, Fung MK, To KF, et al. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 1999;82:498-503.
16. Slotky M, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, et al. The expression of the ubiquitin ligase subunit Cks1 in human breast cancer. Breast Cancer Res 2005;7:R737-44.
17. Inui N, Kitagawa K, Miwa S, Hattori T, Chida K, Nakamura H, et al. High expression of Cks1 in human non-small cell lung carcinomas. Biochem Biophys Res Commun 2003;303:978-84.
18. Masuda TA, Inoue H, Nishida K, Sonoda H, Yoshikawa Y, Kakeji Y, et al. Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res 2003;9:5693-8.
19. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005;103:1336-46.
20. Huang CW, Lin CY, Huang HY, Liu HW, Chen YJ, Shih DF, et al. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes? Ann Surg Oncol 2010;17:907-22.
21. Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006;119:599-607.
22. Kawakami K, Enokida H, Tachiwada T, Nishiyama K, Seki N, Nakagawa M. Increased SKP2 and CKS1 gene expression contributes to the progression of human urothelial carcinoma. J Urol 2007;178:301-7.
23. Kitajima S, Kudo Y, Ogawa I, Bashir T, Kitagawa M, Miyauchi M, et al. Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation. Am J Pathol 2004;165:2147-55.
24. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007;109:4995-5001.
25. Wolden SL, Zelefsky MJ, Kraus DH, Rosenzweig KE, Chong LM, Shaha AR, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:1105-10.
26. Li SH, Li CF, Sung MT, Eng HL, Hsiung CY, Huang WW, et al. Skp2 is an independent prognosticator of gallbladder carcinoma among p27(Kip1)-interacting cell cycle regulators: an immunohistochemical study of 62 cases by tissue microarray. Mod Pathol 2007;20:497-507.
27. Wang XC, Tian LL, Tian J, Li D, Wang Y, Wu H, et al. Overexpression of Cks1 increases the radiotherapy resistance of esophageal squamous cell carcinoma. J Radiat Res 2012;53:72-8.
28. Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 2010;46:1967-78.
29. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol 2008;20:264-9.
30. Cao XJ, Hao JF, Yang XH, Xie P, Liu LP, Yao CP, et al. Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med Oncol 2011;29:263-71.
31. Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 2011;98:15-22.
32. Wang XC, Tian LL, Tian J, Wu HL, Meng AM. Overexpression of Cks1 is associated with poor survival by inhibiting apoptosis in breast cancer. J Cancer Res Clin Oncol 2009;135:1393-401.
33. Lee EK, Kim DG, Kim JS, Yoon Y. Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supporting NF-kappaB-dependent expression of interleukin-8. Cancer Res 2011;71:6827-35.
34. Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM, Wang F. Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer 2008;123:543-51.
35. Chow LS, Lam CW, Chan SY, Tsao SW, To KF, Tong SF, et al. Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. Oncogene 2006;25:310-6.
36. Pines J. Cell cycle: reaching for a role for the Cks proteins. Curr Biol 1996;6:1399-402.
37. Urbanowicz-Kachnowicz I, Baghdassarian N, Nakache C, Gracia D, Mekki Y, Bryon PA, et al. ckshs expression is linked to cell proliferation in normal and malignant human lymphoid cells. Int J Cancer 1999;82:98-104.
38. Spruck CH, de Miguel MP, Smith AP, Ryan A, Stein P, Schultz RM, et al. Requirement of Cks2 for the first metaphase/anaphase transition of mammalian meiosis. Science 2003;300:647-50.
39. Martinsson-Ahlzen HS, Liberal V, Grunenfelder B, Chaves SR, Spruck CH, Reed SI. Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol 2008;28:5698-709.
40. Radulovic M, Crane E, Crawford M, Godovac-Zimmermann J, Yu VP. CKS proteins protect mitochondrial genome integrity by interacting with mitochondrial single-stranded DNA-binding protein. Mol Cell Proteomics 2010;9:145-52.
41. Kang MA, Kim JT, Kim JH, Kim SY, Kim YH, Yeom YI, et al. Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer. J Cancer Res Clin Oncol 2009;135:761-9.
42. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676-84.
43. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, et al. Cyclin E ablation in the mouse. Cell 2003;114:431-43.
44. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
45. Payton M, Scully S, Chung G, Coats S. Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors. Oncogene 2002;21:8529-34.
46. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, et al. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009;100:1002-11.
47. Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W, et al. Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene 1998;17:2637-43.
48. Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO, et al. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol 1999;19:612-22.
49. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
50. Zariwala M, Liu J, Xiong Y. Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins. Oncogene 1998;17:2787-98.